Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma

Haderlein, Marlen; Scherl, Claudia; Semrau, Sabine; Lettmaier, Sebastian; Hecht, Markus; Erber, Ramona; Iro, Heinrich; Fietkau, Rainer; Agaimy, Abbas

doi:10.1007/s00066-017-1196-8

Cited by 29 publications

(24 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Haderlein et al examined the expression of Her2/neu, hormone receptors as well as PD‐L1 by using 67 SDC cases and documented that Her2/neu was independent worse prognostic factor. PD‐L1 overexpression was found in 16.4% of patients when setting in at least 5% of tumor cells showing either moderate or strong staining as the cut‐off value . In our present study, PD‐L1 expression on tumor cells was significantly associated with unfavorable prognosis.…”

Section: Discussioncontrasting

confidence: 72%

“…Although there have been some reports on the association between salivary gland carcinoma and PD‐L1 or PD‐L2, to the best of our knowledge, a few reports on PD‐L1/PD‐L2 in SDC have been found in the English literature . Mukaigawa et al examined the expression of PD‐L1 using 219 surgically resected salivary gland carcinomas.…”

Section: Discussionmentioning

confidence: 99%

“…9,10 There have been some reports on the association between salivary gland carcinoma and PD-L1 or PD-L2. [11][12][13][14][15] We examined the expressions of immune checkpoint ligands PD-L1/PD-L2 and PD-1, and the correlation of clinicopathological findings, including prognosis.…”

mentioning

confidence: 99%

“…Relationship between the expression programed death ligand-1 (PD-L1) and various factors4 | DISCUSSIONIn this study, we demonstrated that high PD-L1 expression was significantly associated with unfavorable prognosis in the high-grade salivary gland tumor, SDC. However, PD-L2 expression was not associated with prognosis.Although there have been some reports on the association between salivary gland carcinoma and PD-L1 or PD-L2, to the best of our knowledge, a few reports on PD-L1/PD-L2 in SDC have been found in the English literature 11,12,14. Mukaigawa et al 12 examined the expression of PD-L1 using 219 surgically resected salivary gland carcinomas.…”

mentioning

confidence: 99%

See 3 more Smart Citations

The expression of programed death ligand‐1 could be related with unfavorable prognosis in salivary duct carcinoma

Satô

Akiba

Kawahara

et al. 2018

J Oral Pathology Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 72%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

The expression of programed death ligand‐1 could be related with unfavorable prognosis in salivary duct carcinoma

Satô

Akiba

Kawahara

et al. 2018

J Oral Pathology Medicine

View full text Add to dashboard Cite

show abstract

“…Despite the advancements in surgery, systemic therapy and radiotherapy, the prognosis of SDC remains meager (6). Despite showing trends toward improved local control, especially the role of adjuvant radiotherapy remains unclear (6,(17)(18)(19)(20). These tumors are currently treated in analogy to other MSGT.…”

Section: Introductionmentioning

confidence: 99%

Intensity Modulated Radiotherapy (IMRT) With Carbon Ion Boost in the Multimodal Treatment of Salivary Duct Carcinoma

et al. 2019

View full text Add to dashboard Cite

Background: To assess outcomes and treatment related toxicity following intensity-modulated radiotherapy (IMRT) and a Carbon Ion Radiotherapy (CIRT) boost for salivary duct carcinoma (SDC). Methods: Twenty-eight consecutive patients with SDC who underwent a postoperative (82%) or definitive (18%) radiation therapy between 2010 and 2017 were assessed in this retrospective single-center analysis. CIRT boost was delivered with median 18 Gy(RBE) in 6 daily fractions, followed by an TomoTherapy ®-based IMRT (median 54 Gy in 27 daily fractions). Treatment-related acute toxicity was assessed according to CTCAE Version 4. Results: Tumors were most commonly located in the major salivary glands (n = 25; 89%); 23 patients (82%) received previous surgery (R0: 30%; R1: 57%; R2: 4%; RX: 19%). Median follow-up was 30 months. Four patients (14%) experienced a local relapse and 3 (11%) developed locoregional recurrence. The two-year local control (LC) and locoregional control (LRC) was 96 and 93%, respectively. Median disease-free survival (DFS) was 27 months, metastasis-free survival (MFS) was 69 months, and overall survival (OS) was 93 months. Acute grade 3 toxicity occurred in 11 patients (mucositis, dermatitis, xerostomia; n = 2 each (7%) were the most common) and 2 osteonecroses of the mandibular (grade 3) occurred. No patients experienced grade ≥4 toxicities. Conclusions: Multimodal therapy approaches with surgery followed by IMRT and CIRT boost for SDC leads to good local and locoregional disease control. However, the frequent occurrence of distant metastases limits the prognosis and requires optimization of adjuvant systemic therapies.

show abstract

Role of HER2 in Prognosis of Salivary Duct Carcinoma: A Systematic Review and Meta‐Analysis

et al. 2022

View full text Add to dashboard Cite

Objectives Salivary duct carcinoma (SDC) is a rare, aggressive malignancy with a poor prognosis. These tumors frequently stain positive for HER2/ErbB2, but data on the prognostic significance of HER2 status in SDC are mixed. We sought to determine whether HER2 status affects survival outcomes in SDC. Methods PubMed, Embase, and Web of Science databases were searched from inception to October 2020. Eligibility was restricted to studies reporting HER2/ErbB2 overexpression in histologically confirmed de novo SDC or SDC ex pleomorphic adenoma, with corresponding overall (OS) and disease‐free (DFS) survival measures. Separate multivariable and univariable meta‐analyses were performed using random‐effects models. Statistical heterogeneity was estimated by Cochran's Q and I2 tests. Funnel plots were generated and Egger's test was used to assess for publication bias. The risk of bias was assessed with the Newcastle‐Ottawa Scale. Results Of 183 unique citations, 14 studies of 663 patients were included. Most included studies determined HER2 status according to ASCO/CAP guidelines. The univariable meta‐analysis did not reveal an effect between HER2 status and OS (HR 1.09, 95% CI 0.84–1.42). In the multivariable analysis, HER2 positivity was associated with a HR of 1.49 for OS (95% CI 0.96–2.30). Fewer studies reported data for DFS than OS, with no relationship between HER2 status and DFS found on multivariable or univariable meta‐analyses. Conclusion In patients with salivary duct carcinoma, HER2 positivity was not found to be associated with worse overall survival. This information may be useful when counseling patients and considering treatment options. Laryngoscope, 133:476–484, 2023

show abstract

Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma

Cited by 29 publications

References 30 publications

The expression of programed death ligand‐1 could be related with unfavorable prognosis in salivary duct carcinoma

The expression of programed death ligand‐1 could be related with unfavorable prognosis in salivary duct carcinoma

Intensity Modulated Radiotherapy (IMRT) With Carbon Ion Boost in the Multimodal Treatment of Salivary Duct Carcinoma

Role of HER2 in Prognosis of Salivary Duct Carcinoma: A Systematic Review and Meta‐Analysis

Contact Info

Product

Resources

About